Glenmark has launched Nitric Oxide Nasal Spray for Covid 19 treatment in India. FabiSpray’ was launched by Glenmark in partnership with ‘SaNOtize’.
“Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 percent in 24 hours and 99 percent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in COVID-19 patients. Glenmark to market NONS under the brand name FabiSpray,” the company said in a statement.
Nitric Oxide Nasal Spray will be useful in the treatment of adult patients with COVID-19 who have a high risk of progression of the disease. FabiSpray, Nitric Oxide Nasal Spray (NONS), according to Glenmark, is designed to kill the virus in the upper airways.
It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS when sprayed over the nasal mucosa. It acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs, the company explained.
FabiSpray has been developed for the treatment of adult patients of Covid-19 who have a high risk of progression of the disease. “We are confident it will offer patients a much needed and timely therapy option,” Glenmark Pharmaceuticals Ltd’s Chief Commercial Officer Robert Crockart said.
“In the current scenario, with new emerging variants exhibiting high transmissibility, NONS provides a useful option in India’s fight against COVID-19. As per studies conducted in the Utah State University USA, NONS is proven to kill 99.9 percent of SARS-Cov-2 virus including Alpha, Beta, Gamma, Delta, and Epsilon variant within 2 minutes,” said Dr. Monika Tandon, Senior VP and Head of Clinical Development in Glenmark Pharmaceuticals Ltd.